Get the Stockscreener App
12.27
2.25%
0.27
Evommune Inc stock is traded at $12.27, with a volume of 249.08K.
It is up +2.25% in the last 24 hours and down -6.41% over the past month.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
See More
Previous Close:
$12.00
Open:
$11.87
24h Volume:
249.08K
Relative Volume:
0.32
Market Cap:
$445.30M
Revenue:
$10.00M
Net Income/Loss:
$-75.99M
P/E Ratio:
-5.1397
EPS:
-2.3873
Net Cash Flow:
$-80.36M
1W Performance:
-7.26%
1M Performance:
-6.41%
6M Performance:
-47.99%
1Y Performance:
+0.00%
1-Day Range:
$11.87
$12.46
1-Week Range:
$11.70
$13.13
52-Week Range:
$10.47
$33.20
Evommune Inc Stock (EVMN) Company Profile
Name
Evommune Inc
Sector
Industry
Phone
(650) 223-7745
Address
1891 PAGE MILL RD, PALO ALTO
Compare EVMN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
12.27 | 492.48M | 10.00M | -75.99M | -80.36M | -2.3873 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-26 | Resumed | Oppenheimer | Outperform |
| Jan-22-26 | Initiated | Oppenheimer | Outperform |
| Jan-08-26 | Initiated | Raymond James | Strong Buy |
| Jan-06-26 | Initiated | H.C. Wainwright | Buy |
| Dec-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-01-25 | Initiated | Evercore ISI | Outperform |
| Dec-01-25 | Initiated | Leerink Partners | Outperform |
| Dec-01-25 | Initiated | Morgan Stanley | Overweight |
| Dec-01-25 | Initiated | William Blair | Outperform |
View All
Evommune Inc Stock (EVMN) Latest News
Evommune (EVMN) Financial Update: EPS Misses Its Estimate in Latest Trading; Trading Move: Shares Move 10.63% Down in Latest TradingProfit Margin Analysis - vinanet.vn
Evommune (NYSE:EVMN) Trading Down 6.9%Here's What Happened - MarketBeat
Evommune Inc (EVMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Evommune Inc. (EVMN) Rises 4.12% to $14.65 as Clinical-Stage Biotech Draws Fresh InterestHull Moving Average - vinanet.vn
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - Stocktwits
Evommune (EVMN) Slips 0.42% to $14.06 as Consolidation Tightens Around Key SupportBreakout Stock Alerts - Vinanet
HC Wainwright Issues Negative Estimate for Evommune Earnings - MarketBeat
Evommune Inc. (EVMN) Holds Steady at $14.07 as Consolidation ContinuesDebt Free Companies - vinanet.vn
Analysts Conflicted on These NA Names: Bob’s Discount Furniture, Inc. (BOBS), Evommune, Inc. (EVMN) and Once Upon a Farm, PBC (OFRM) - The Globe and Mail
Evommune, Inc. (NYSE:EVMN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Evommune (NYSE:EVMN) Price Target Cut to $29.00 by Analysts at Royal Bank Of Canada - MarketBeat
Evommune, Inc. Stock 12‑Month Price Target Cut to $30.11, Implies 125% Upside - TradingView
Evommune Inc (EVMN) Stock News Today - TradingKey
RBC Adjusts PT on Evommune to $29 From $30, Maintains Outperform Speculative Risk Rating - marketscreener.com
Evommune Inc (EVMN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
EVMN: Advancing two novel anti-inflammatory therapies with strong clinical and financial momentum - TradingView
EVMN: Strong cash reserves support key clinical milestones despite higher losses and no Q2 revenue - TradingView
Evommune reports Q2 2026 net loss of $32.2M, cash $288.0M; EVO756 Phase 2b AD readout due Sept 2026 - TradingView
Evommune, Inc. 2Q 2026: Revenue $0 Net loss $53.9M — 10-Q Summary - TradingView
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights - Business Wire
Migraine Biotech Doses First Patient in Phase 2b EVO756 Trial - Streetwise Reports
Evommune Inc. (EVMN) Advances 2.76% as Shares Test Key Resistance Near $14Aggressive Growth Picks - vinanet.vn
Evommune Inc. (EVMN) Holds Near $13.09 as Biotech Stock Consolidates Between Key LevelsUndervalued Stocks - dars.gov.et
Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), LB Pharmaceuticals, Inc. (LBRX) and SpaceX (SPCX) - The Globe and Mail
896,700 Shares in Evommune, Inc. $EVMN Purchased by Janus Henderson Group PLC - MarketBeat
HC Wainwright Reiterates Neutral Rating for Evommune (NYSE:EVMN) - MarketBeat
Evommune stock: H.C. Wainwright reiterates Neutral rating By Investing.com - Investing.com India
Evommune stock: H.C. Wainwright reiterates Neutral rating - Investing.com
EVMN Q1 2026 Earnings: Narrower Loss Beats Estimates by 15.6% Amid No RevenuePre-Earnings Drift - vinanet.vn
Evommune doses first patient in migraine prevention trial By Investing.com - Investing.com Nigeria
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis - Yahoo Finance
EVMN Q1 2026 Earnings: EPS Surprises to the Upside as Clinical Pipeline AdvancesRevenue Beat Analysis - vinanet.vn
Evommune Inc (EVMN) Institutional Confidence - TradingKey
Evommune Inc (EVMN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Evommune Inc (EVMN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Evommune, Inc. $EVMN Stake Lessened by Octagon Capital Advisors LP - MarketBeat
Evommune Inc (EVMN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
EVMN|Evommune Inc|Price:11.480|Chg%:+0.120 - TradingKey
EVMN|Evommune Inc|Price:11.600|Chg%:+0.350 - TradingKey
Evommune Inc (EVMN) Cash Flow - TradingKey
Evommune Inc (EVMN) Income Statement - TradingKey
Evommune, Inc. Revenue Breakdown – NYSE:EVMN - TradingView
EVMN|Evommune Inc|Price:13.490|Chg%:+0.470 - TradingKey
Evommune Inc (EVMN) Balance Sheet - TradingKey
Evommune Inc (EVMN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Evommune Inc (EVMN) Valuation: PE, PB & Fair Value Analysis - TradingKey
EVMN|Evommune Inc|Price:11.360|Chg%:+0.060 - TradingKey
Evommune Inc. (EVMN) Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineFinancial Health Score - po-news-eg.net
Evommune (EVMN) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEarnings Call Transcript - vinanet.vn
Evommune Inc. (EVMN) Q1 2026 Earnings: EPS Surprise Exceeds Expectations Amid Pre-Revenue StageBanking Earnings Report - dars.gov.et
Evommune Inc. (EVMN) Q1 2026 Earnings: Narrower Loss Highlights Cost Discipline for Pre-Revenue BiotechBalance Sheet Strength - vinanet.vn
Evommune Inc Stock (EVMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Evommune Inc Stock (EVMN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KIRSCH ARTHUR S | Director |
Jul 07 '26 |
Buy |
13.30 |
10,000 |
133,000 |
10,000 |
| Drew Janice Suzann | Chief of Dev. Operations |
Jun 22 '26 |
Option Exercise |
3.15 |
20,000 |
63,063 |
87,794 |
| Drew Janice Suzann | Chief of Dev. Operations |
Jun 22 '26 |
Sale |
22.63 |
20,000 |
452,600 |
67,794 |
| Patel Jeegar Pravinkumar | Chief Scientific Officer |
Jun 22 '26 |
Option Exercise |
3.84 |
1,488 |
5,714 |
47,891 |
| Patel Jeegar Pravinkumar | Chief Scientific Officer |
Jun 22 '26 |
Sale |
22.50 |
1,488 |
33,480 |
46,403 |
| Pena Luis C. | President & CEO |
Jun 22 '26 |
Sale |
22.71 |
7,438 |
168,917 |
630,458 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):